Status:
COMPLETED
The Safety and Efficacy of RIC on Adult Moyamoya Disease
Lead Sponsor:
Capital Medical University
Conditions:
Moyamoya Disease
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
There are a series of symptoms such as ischemic stroke、transient ischemic attack 、hemorrhagic stroke、headache 、seizure and so on in moyamoya disease( MMD) patients .Nowadays, revascularization is the ...
Detailed Description
There are a series of symptoms such as ischemic stroke、transient ischemic attack 、hemorrhagic stroke、headache 、seizure and so on in moyamoya disease. Nowadays, revascularization is the only effective ...
Eligibility Criteria
Inclusion
- Age: 18-60 years
- All of the patients underwent digital subtraction angiography (DSA) and met the current diagnostic criteria recommended by the Research Committee on MMD of the Ministry of Health and Welfare of Japan in 2012.
- mRs≤3
- Informed consent obtained from patient or acceptable patient's surrogate.
Exclusion
- Patients with acute ischemic or hemorrhagic stroke within 3 months.
- Severe hepatic or renal dysfunction.
- Severe hemostatic disorder or severe coagulation dysfunction.
- Severe cardiac diseases.
- Patients with severe existing neurological or psychiatric disease
- Patients with moyamoya syndrome caused by autoimmune disease, Down syndrome , neurofibromatosis, leptospiral infection, or previous skull-base radiation therapy.
- Patients have been done or plan to accept revascularization surgery.
Key Trial Info
Start Date :
July 15 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 2 2021
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04012268
Start Date
July 15 2019
End Date
February 2 2021
Last Update
March 12 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xuanwu Hospital, Capital Medical University
Beijing, Beijing Municipality, China, 100053